Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 32.06
- Piotroski Score 2.00
- Grade Equal-Weight
- Symbol (THRD)
- Company Third Harmonic Bio, Inc.
- Price $12.44
- Changes Percentage (8.65%)
- Change $0.99
- Day Low $11.48
- Day High $12.68
- Year High $16.94
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
- Last Earnings 07/30/2014
- Ex-Dividend for 5/16 Dividend 08/06/2014
- Dividend Payable 08/15/2014
- Today N/A
- Next Earnings (Estimated) 03/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $19.00
- High Stock Price Target $23.00
- Low Stock Price Target $3.60
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.75
- Trailing P/E Ratio -18.95
- Forward P/E Ratio -18.95
- P/E Growth -18.95
- Net Income $-30,824,000
